PFS
IGMS

Prospera Financial Services’s IGM Biosciences IGMS Stock Holding History

Prospera Financial Services’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-98
Closed -$2K – 1197
2022
Q2 		$2K Hold
98
– – ﹤0.01% 1547
2022
Q1 		$3K Buy
+98
New +$1.82K ﹤0.01% 2386

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Prospera Financial Services's IGMS Position: Q3 2022 in Review

Prospera Financial Services sold out of IGM Biosciences (IGMS) in Q3 2022, closing a stake of 98 shares — an estimated $2K sold.

Prospera Financial Services first reported a position in IGMS in Q1 2022 and held it in 2 quarters. The position peaked at $3K in Q1 2022. 92 funds tracked by Wall St. Rank hold IGMS as of Q3 2022.

  • Prospera Financial Services reported no remaining IGM Biosciences position as of Q3 2022 after selling out during the quarter.
  • Prospera Financial Services sold 98 IGM Biosciences shares in Q3 2022, an estimated $2K.
  • Prospera Financial Services first reported a position in IGM Biosciences in Q1 2022 and held it in 2 quarters.
  • Prospera Financial Services's IGM Biosciences position peaked at $3K in Q1 2022.
  • 92 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2022.

Based on Prospera Financial Services's 13F filing for Q3 2022, filed 27 Oct 2022.